(NYSE: NVO) Novo Nordisk A S's forecast annual revenue growth rate of 7.39% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.47%.
Novo Nordisk A S's revenue in 2020 is $19,544,531,250.On average, 3 Wall Street analysts forecast NVO's revenue for 2021 to be $47,418,703,571,400, with the lowest NVO revenue forecast at $45,663,209,295,000, and the highest NVO revenue forecast at $50,669,078,153,000. On average, 3 Wall Street analysts forecast NVO's revenue for 2022 to be $52,178,895,754,700, with the lowest NVO revenue forecast at $50,061,635,955,000, and the highest NVO revenue forecast at $56,273,664,979,000.
In 2023, NVO is forecast to generate $57,121,129,607,500 in revenue, with the lowest revenue forecast at $53,533,054,230,000 and the highest revenue forecast at $60,709,204,985,000.